Semaglutide vs Tirzepatide vs Retatrutide: GLP-1 Class Peptides Compared

The Evolution of Incretin-Based Research Peptides

The GLP-1 receptor agonist class has undergone rapid development over the past decade, progressing from single-receptor agents through dual agonists to triple agonists. Each step has added receptor targets with documented incremental effects in metabolic research. Understanding the mechanistic distinction between semaglutide, tirzepatide, and retatrutide is increasingly important for researchers designing metabolic or adiposity studies.

Semaglutide: The Single GLP-1R Agonist Benchmark

Semaglutide is a 94% sequence-homologue of native GLP-1, acylated with a C18 fatty diacid chain enabling albumin binding and a ~7-day half-life. It acts exclusively at the GLP-1 receptor (GLP-1R), producing the characteristic incretin effects: glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite suppression via hypothalamic GLP-1R expression.

The STEP 1 trial (Wilding et al., NEJM 2021) remains the landmark GLP-1 agonist obesity RCT — once-weekly 2.4mg semaglutide produced 14.9% mean body weight reduction at 68 weeks vs 2.4% placebo. This established semaglutide as the benchmark comparator for all subsequent incretin research.

The SELECT cardiovascular outcomes trial later confirmed a 20% reduction in MACE in overweight/obese patients without diabetes, establishing cardiovascular benefit independent of weight loss.

Tirzepatide: Adding GIP Receptor Agonism

Tirzepatide (developed as Mounjaro/Zepbound) adds GIP receptor (GIPR) agonism to GLP-1R engagement — creating the first approved dual incretin agonist. GIP is an incretin hormone secreted by duodenal K-cells in response to nutrient ingestion. Its effects on adipose tissue and insulinotropic potentiation appear to complement GLP-1R activity in ways still being characterised in the published literature.

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) documented 22.5% mean body weight reduction at 72 weeks with the 15mg dose — significantly exceeding semaglutide's STEP 1 data. The SURPASS-2 head-to-head against semaglutide confirmed tirzepatide's superior HbA1c reduction in T2D patients.

The precise mechanistic contribution of GIPR agonism to tirzepatide's outcomes remains a subject of active research — whether the GIP component primarily contributes via adipose metabolism, tolerability improvement, or central mechanisms is not fully established.

Retatrutide: Adding Glucagon Receptor Agonism

Retatrutide (LY3437943, developed by Eli Lilly) adds glucagon receptor (GCGR) agonism as a third mechanism — making it the first triple incretin agonist in clinical trials. Glucagon receptor activation increases hepatic glucose output and stimulates thermogenesis and lipolysis. When combined with GLP-1R agonism, the glycaemic effects of glucagon are blunted while its thermogenic and hepatic lipolytic effects are preserved.

Phase 2 data (Jastreboff et al., NEJM 2023) showed approximately 24% mean body weight reduction at 48 weeks in the 12mg cohort — the highest published figure for any incretin agonist at Phase 2. Dose-dependent reductions in liver fat fraction (MRI-PDFF) were also documented, of particular interest given the dedicated TRIUMPH-NASH Phase 3 trial.

Retatrutide is not yet approved for any therapeutic indication. Phase 3 TRIUMPH trials (obesity, T2D, cardiovascular, NASH) are ongoing.

Three-Way Comparison

Note: Trial comparisons across different studies, timeframes, and patient populations should be interpreted with caution. Phase 2 data for retatrutide is not directly comparable to Phase 3 data for approved agents.

Research Considerations

For researchers designing metabolic studies, the choice between these compounds depends on the specific pathway of interest:

• GLP-1R-isolated signalling studies: Semaglutide as the cleanest single-target agent
• GIP/GLP-1 dual mechanism research: Tirzepatide — the most clinically characterised dual agonist with head-to-head semaglutide data
• Triple receptor / thermogenic pathway research: Retatrutide — the only triple agonist available for research, with Phase 2 hepatic fat data
• NASH/liver-specific models: Retatrutide has the most dedicated hepatic Phase 3 programme of any incretin-class compound

Important note for Australian researchers: TGA regulatory changes effective October 2024 affect the compounding of GLP-1 class peptides. Researchers should consult current TGA guidance regarding applicable regulatory requirements. All products from Eternal Peptides Wholesale are supplied for qualified laboratory research use only.

Frequently Asked Questions

References

1. Wilding JPH et al. N Engl J Med. 2021;384(11):989-1002 (STEP 1)
2. Jastreboff AM et al. N Engl J Med. 2022;387(3):205-216 (SURMOUNT-1)
3. Jastreboff AM et al. N Engl J Med. 2023;389(6):514-526 (Retatrutide Ph2)